BioNTech SE BNTX

What this company does

BioNTech discovers, develops and commercializes its marketed product and product candidates through an integrated model spanning research, GMP manufacturing, clinical development and commercial capabilities. Its commercial product, Comirnaty, developed in 2020, is an approved mRNA-based COVID-19 vaccine. As of March 2026, the vaccine had been authorized or granted marketing authorization in more than 180 countries and regions worldwide, with over 5 billion doses shipped globally. The company's product candidates span multiple technology platforms, including investigational messenger ribonucleic acid, or mRNA, immunotherapies and protein-based therapeutics such as monoclonal, bispecific and antibody-drug conjugate antibodies. Its oncology pipeline consists of 16 clinical programs, with more than 25 Phase 2 and Phase 3 clinical trials and ten combination trials ongoing involving its investigational bispecific antibody pumitamig. In infectious diseases, it develops vaccines and therapeutics addressing conditions caused by respiratory viruses, latent viruses, bacteria and parasites. The company operates a GMP-certified manufacturing facility at its headquarters in Mainz, Germany, for the production of iNeST immunotherapies. BioNTech was founded in 2008.

Written from the business description in BioNTech SE's annual report to the U.S. Securities and Exchange Commission, filed 10 March 2026. Every sentence was checked against that document before publication.